General description
Survivin (TIAP, BIRC5), (16 kDa) is a member of the inhibitors of apoptosis (IAP)/BIR-domain-containing proteins (BIRP) gene family. It contains only one baculoviral IAP repeat domain (BIR) and lacks the domain, really interesting new gene (RING) finger. Survivin gene is localized on human chromosome 17q25.3. Survivin is highly expressed in embryonic and fetal tissues. It is selectively expressed during mitosis in the G2/M phase and is localized to mitotic spindle microtubules.
Specificity
Anti-Survivin produced using a peptide corresponding to amino acids 122-142 at the carboxyl-terminus of human survivin. This sequence is highly conserved (>70%) in rat and mouse survivin. Anti-Survivin recognizes human, mouse and rat survivin. The antibody is suitable for immunoblotting.
Immunogen
synthetic peptide corresponding to the C-terminus of human survivin (amino acids 122-142). This sequence is highly conserved (>70%) in rat and mouse survivin.
Application
Anti-Survivin antibody produced in rabbit has been used in:
- immunohistochemistry
- western blotting
- immunocytochemistry
Biochem/physiol Actions
Survivin is required for cell viability maintenance in mitosis, potentially coupling apoptosis to control cell division. Antisense targeting of survivin results in increased caspase-3 activity. This occurs during mitosis, dysregulation of the centrosome, and mitotic progression, and cell death at the G2/M phase of the cell cycle. Survivin associates with cyclin-dependent kinase p34cdc2 on the mitotic apparatus, and is phosphorylated at Thr34 by p34cdc2-cyclin B1. . Survivin is overexpressed in a variety of human tumors, including adenocarcinomas of lungs, pancreas, breast, colorectal and stomach. It is also present in elevated levels in prostate, high-grade non-Hodgkin lymphoma, and neuroblastomas. Expression of a phosphorylation defective survivin mutant Thr34 to Ala triggers apoptosis in human melanoma cell lines in vitro and in vivo and inhibits melanoma tumor growth in mice. This makes survivin to be useful in cancer therapy by its direct effect anti-apoptotic pathway.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Storage and Stability
For continuous use, store at 2-8 °C for up to one month.For prolonged storage, freeze in working aliquots at −20 °C. Repeated freezing and thawing is not recom-mended. Storage in frost-free freezers is also notrecommended. If slight turbidity occurs upon prolongedstorage, clarify the solution by centrifugation beforeuse. Working dilutions should be discarded if not usedwithin 12 hours.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.